Corticobasal Degeneration (CBD) is a rare neurodegenerative disorder that affects cognition, language, behavior, and movement. CBD is an atypical Parkinsonian syndrome with some features of Parkinson's disease and PSP (Progressive Supranuclear Palsy), but it has distinct pathology. It is a four-repeat tauopathy marked by abnormal tau protein buildup in the brain, causing neuronal degeneration, especially in the cortex.

CBD often presents with asymmetric motor disturbances (e.g. stiffness, slowness, myoclonus, and apraxia) and cognitive impairment, such as aphasia, memory loss, and executive dysfunction. Other symptoms include dystonia, apraxia, and alien limb syndrome. Due to its similar symptoms, CBD is often misdiagnosed as Progressive Supranuclear Palsy (PSP), Frontal Behavioral-Spatial Syndrome (FBS), nonfluent/agrammatic variant of Primary Progressive Aphasia (naPPA), or Parkinson's disease, but it progresses more rapidly and does not respond well to medications for Parkinson's disease.

Advancing our knowledge of dependable neuroimaging biomarkers in CBD can lead to accurate and early diagnosis, support suitable disease management strategies, and aid in the evaluation of new treatments during clinical trials.